Τίτλος:
Real world data from the use of secukinumab in the treatment of moderate-to-severe psoriasis, including scalp and palmoplantar psoriasis: A 104-week clinical study
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Several clinical studies demonstrated the safety and efficacy of the interleukin-17 inhibitor secukinumab in the systemic treatment of moderate-to-severe psoriasis, as well as psoriatic arthritis (PsA) in adults, whereas real-world data is limited. A single-center clinical study was performed to evaluate in real-world practice the efficacy of secukinumab up to Week 104 of treatment in moderate-to-severe chronic plaque psoriasis, including scalp and palmoplantar involvement, according to Physician Global Assessment (PGA), PASI75/90/100 and scalp, and palmoplantar PGA. Drug survival, the safety profile of secukinumab, and patient's quality of life were also assessed during a 2-year observation period. Out of 83 patients included, 56.3% were biologic-naïve, and 94% had scalp, 25.3% palmoplantar, and 43.9% joint involvement. At Week 16, PASI75/PASI90/PASI100 were observed in 83.8/70.0/46.3%, respectively. Scalp and palmoplantar PGA were rapidly improved, with 98.7 and 95.5%, respectively, reaching clear/almost clear skin at Week 16. After 104 weeks, drug survival was 74.5%. A significant improvement of the quality of life was observed. Biologic-naïve patients without coexisting PsA benefited the most. Real-world data demonstrated secukinumab efficacious in chronic plaque psoriasis, including specific locations such as scalp and palmoplantar psoriasis with a safety profile similar to that in clinical trials. © 2019 Wiley Periodicals, Inc.
Συγγραφείς:
Rompoti, N.
Katsimbri, P.
Kokkalis, G.
Boumpas, D.
Ikonomidis, I.
Theodoropoulos, K.
Rigopoulos, D.
Papadavid, E.
Περιοδικό:
Dermatologic Therapy
Εκδότης:
Blackwell Publishing Inc.
Λέξεις-κλειδιά:
cyclosporine; etretin; interleukin 12 antibody; interleukin 23 antibody; methotrexate; secukinumab; steroid; topical agent; tumor necrosis factor inhibitor; vitamin D; interleukin 17; monoclonal antibody; secukinumab, adult; aged; Article; chronic disease; Dermatology Life Quality Index; disease severity; drug efficacy; drug safety; drug withdrawal; edema; external otitis; fatigue; female; folliculitis; guttate psoriasis; human; low drug dose; major clinical study; male; medical record review; monotherapy; nail psoriasis; paresthesia; psoriasis; Psoriasis Area and Severity Index; psoriasis inversa; psoriasis vulgaris; psoriatic arthritis; pustulosis palmoplantaris; retrospective study; scalp psoriasis; steroid therapy; systemic therapy; topical treatment; treatment duration; treatment response; ankle; dose response; follow up; middle aged; psoriasis; scalp; severity of illness index; time factor; treatment outcome; young adult, Adult; Aged; Ankle; Antibodies, Monoclonal, Humanized; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Interleukin-17; Male; Middle Aged; Psoriasis; Scalp; Severity of Illness Index; Time Factors; Treatment Outcome; Young Adult
